Important Safety Information On The Association Of Zevalin (ibritumomab Tiuxetan) With Severe Mucocutaneous Reactions - Berlex Canada Inc.
Zevalin Safety Recall Summary Zevalin (ibritumomab tiuxetan), a cancer treatment drug distributed across Canada, is being recalled due to its association with severe skin and mouth reactions. The drug has been linked to serious mucocutaneous reactions that affect the skin and mucous membranes. This recall affects all patients and healthcare providers who use or prescribe this medication in Canada.
- Category
- drug recall
- Country
- Canada
- Agency
- HC-DRUGS
- Recall date
- 2005-12-07
- Status
- Closed
- Distribution
- Canada-wide
Official recall notice from HC-DRUGS
Recall details on Nibble Recalls: https://trynibble.app/recalls/df0c5bdd-1cce-40e0-8b6c-fae668c8807b